Our Pipeline
Each agent in our cutting edge platform emerged from rigorous structure–activity campaigns spanning 400+ candidates, multi-species surgical models, and practical refinement in partnership with leading surgeons. The technology delivers bright, selective nerve contrast, rapid tissue kinetics, and seamless compatibility with existing clinical imaging systems. Following extensive preclinical characterization and clinical development, we are excited to bring the game-changing Nerve Trace technology to clinical trials.
Agent | Indication | Library Synthesis & Screening | Lead Optimization | IND Enabling | Phase I/II |
|---|---|---|---|---|---|
NerveTrace Dx IND approved rapid nerve damage assessment | Orthopedic, Reconstructive, Head & Neck | ||||
NerveTrace Total High contrast in PNS & CNS with extended PK | Prostatectomy, Brain & Skull Base, Spine | ||||
NerveTrace 800 Compatible with clinical imaging systems (ICG) | Colorectal, Prostatectomy, Hysterectomy |
Rapid, low-risk, regulatory pathway with capital efficient trials towards FDA approval.